

Indonesia Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Indonesia			
2. Grant number(s): 1618-IDN-25b-Y / 15-IDN-08h-Y			
3. Date of Decision Letter: 14 December 2017			
4. Date of the Partnership Framework Agreement: 30 December 2014			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID			
8. Programme duration²: 2016 - 2018			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2016-2017	2018	Total ³
Routine Programme (US\$)	10,812,000 ⁴	8,131,000	18,943,000
10. Vaccine introduction grant: a VIG of US\$ 3,688,500 was disbursed to Indonesia on 28 November 2014.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁵			
Number of vaccines to be purchased with Gavi funds		2018	
IPV Routine Programme (doses)		4,200,000	
Annual Amounts (US\$)		8,131,000	
12. Procurement agency: Not applicable.			
13. Self-procurement: Self-procurement applies. Please refer to the partnership framework agreement terms and conditions.			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2018.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

<p>14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Indonesia is encouraged to contribute to vaccine and/or supply costs for IPV.</p>							
<p>15. Operational support for catch-up campaigns: Not applicable</p>							
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2018</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat						
<p>17. Financial clarifications: Not applicable</p>							
<p>18. Other conditions:</p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Indonesia envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Indonesia.</p>							

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
14 December 2017